SGX:H02Pharmaceuticals
Haw Par (SGX:H02) Stock Drifts Lower While Margins Stay Exceptionally Rich
Haw Par headed into this earnings release with the stock grinding lower for months, down about 8% over the last quarter, even as its P/E sat below the wider Asian pharmaceuticals pack. The headline in this half-year period is profitability. Net income of about S$107.9m on revenue of S$115.9m translates into very high margins, which matters far more than the soft share price tape.
For short term traders the drift in Haw Par may look uninspiring. For long term holders the focus is now on...